658 related articles for article (PubMed ID: 12525232)
41. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men.
Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Palefsky JM
Am J Med; 2000 Jun; 108(8):634-41. PubMed ID: 10856411
[TBL] [Abstract][Full Text] [Related]
42. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.
Hoerger TJ; Harris R; Hicks KA; Donahue K; Sorensen S; Engelgau M
Ann Intern Med; 2004 May; 140(9):689-99. PubMed ID: 15126252
[TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls.
Ito K
JAMA Netw Open; 2020 Dec; 3(12):e2027584. PubMed ID: 33258906
[TBL] [Abstract][Full Text] [Related]
44. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Jonas DE; Reuland DS; Reddy SM; Nagle M; Clark SD; Weber RP; Enyioha C; Malo TL; Brenner AT; Armstrong C; Coker-Schwimmer M; Middleton JC; Voisin C; Harris RP
JAMA; 2021 Mar; 325(10):971-987. PubMed ID: 33687468
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
46. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.
Yeh JM; Hur C; Ward Z; Schrag D; Goldie SJ
Gut; 2016 Apr; 65(4):563-74. PubMed ID: 25779597
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of lung MRI in lung cancer screening.
Allen BD; Schiebler ML; Sommer G; Kauczor HU; Biederer J; Kruser TJ; Carr JC; Hazen G
Eur Radiol; 2020 Mar; 30(3):1738-1746. PubMed ID: 31748855
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.
Meza R; Jeon J; Toumazis I; Ten Haaf K; Cao P; Bastani M; Han SS; Blom EF; Jonas DE; Feuer EJ; Plevritis SK; de Koning HJ; Kong CY
JAMA; 2021 Mar; 325(10):988-997. PubMed ID: 33687469
[TBL] [Abstract][Full Text] [Related]
49. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals.
van Kempen BJ; Spronk S; Koller MT; Elias-Smale SE; Fleischmann KE; Ikram MA; Krestin GP; Hofman A; Witteman JC; Hunink MG
J Am Coll Cardiol; 2011 Oct; 58(16):1690-701. PubMed ID: 21982314
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.
Zhao Z; Wang Y; Wu W; Yang Y; Du L; Dong H
JAMA Netw Open; 2022 May; 5(5):e2213634. PubMed ID: 35608858
[TBL] [Abstract][Full Text] [Related]
51. Population impact of lung cancer screening in the United States: Projections from a microsimulation model.
Criss SD; Sheehan DF; Palazzo L; Kong CY
PLoS Med; 2018 Feb; 15(2):e1002506. PubMed ID: 29415013
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of intensive smoking cessation therapy among patients with small abdominal aortic aneurysms.
Mani K; Wanhainen A; Lundkvist J; Lindström D
J Vasc Surg; 2011 Sep; 54(3):628-36. PubMed ID: 21620630
[TBL] [Abstract][Full Text] [Related]
53. Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
Veronesi G; Navone N; Novellis P; Dieci E; Toschi L; Velutti L; Solinas M; Vanni E; Alloisio M; Ghislandi S
Lung Cancer; 2020 May; 143():73-79. PubMed ID: 32234647
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of a smoking cessation program implemented at the time of surgery for lung cancer.
Slatore CG; Au DH; Hollingworth W
J Thorac Oncol; 2009 Apr; 4(4):499-504. PubMed ID: 19204575
[TBL] [Abstract][Full Text] [Related]
55. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
[TBL] [Abstract][Full Text] [Related]
56. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
Sprague BL; Stout NK; Schechter C; van Ravesteyn NT; Cevik M; Alagoz O; Lee CI; van den Broek JJ; Miglioretti DL; Mandelblatt JS; de Koning HJ; Kerlikowske K; Lehman CD; Tosteson AN
Ann Intern Med; 2015 Feb; 162(3):157-66. PubMed ID: 25486550
[TBL] [Abstract][Full Text] [Related]
57. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
Blake GJ; Ridker PM; Kuntz KM
Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
[TBL] [Abstract][Full Text] [Related]
58. Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review.
Raymakers AJN; Mayo J; Lam S; FitzGerald JM; Whitehurst DGT; Lynd LD
Appl Health Econ Health Policy; 2016 Aug; 14(4):409-418. PubMed ID: 26873091
[TBL] [Abstract][Full Text] [Related]
59. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
